Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor

Hey! I'd love to hear your thoughts, send me a voice note.

Researchers rated 50.4% of the 125 most-liked ADHD videos on TikTok as misleading, and only 19.2% as useful. In a sample of 600 comments on those videos, 42% showed self-attribution — viewers applying the symptoms or the diagnosis to themselves. Two hosts break down why arguing about the label is the clinical error, the script that validates the experience without conceding the diagnosis, and how to run the assessment you would have run anyway.

Full script: https://psychnpfellowship.com/patient-self-diagnosis-tiktok-pmhnp-confidence-script-2026/

Hey! I'd love to hear your thoughts, send me a voice note.

A benzodiazepine taper protocol for PMHNPs built on the 2025 joint guideline: 5-10% cuts every 2-4 weeks, when to pause, and how to get through the last steps.

In this Deep Dive episode, two hosts walk through “Benzodiazepine Taper Protocol: 2026 PMHNP Guide” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC.

Key takeaways:

• The 2025 joint guideline, backed by 10 societies including AANP and the APA, recommends starting with 5-10% dose cuts every 2-4 weeks and rarely going faster than 25% every 2 weeks.

• Physical dependence is expected after steady use. Withdrawal risk is real with use on 4 or more days a week for 1-3 months at moderate to high doses, or for 3 months or longer at any dose.

• Fixed milligram cuts get steeper as the dose drops. A 0.25 mg cut is 12.5% at 2 mg of clonazepam and 50% at 0.5 mg.

• When withdrawal symptoms show up, slow or pause the taper before adding another drug. Do not use flumazenil to speed things up.

• The goal can be a lower dose, not zero. Offer CBT or CBT-I alongside the taper, and watch for withdrawal for 2-4 weeks after the last dose.

Read the full article: https://psychnpfellowship.com/benzodiazepine-taper-protocol-pmhnp-2026/

Explore the Psych NP Fellowship: https://psychnpfellowship.com/programs/

This content is for educational purposes and does not replace individualized clinical judgment or supervision.

Hey! I'd love to hear your thoughts, send me a voice note.

Serious rash risk tracks the speed of dose escalation, not the final dose — slow titration moves it from roughly 1 in 100 to about 1 in 2,500. Two hosts walk the six-week bipolar schedule step by step (25 → 50 → 100 → 200 mg, two weeks at each of the first two steps), the interactions that change every number (valproate halves them, enzyme inducers double them, estrogen-containing contraceptives complicate them), and how to tell a benign rash from the one that means stop now.

Protocol and dosing tables: https://psychnpfellowship.com/lamotrigine-rash-titration-protocol-pmhnp-2026/

Hey! I'd love to hear your thoughts, send me a voice note.

No classic psychedelic is FDA-approved for any psychiatric indication, and psilocybin, MDMA and LSD all remain Schedule I — yet patients are asking about them weekly. On July 14, 2026 the FDA published a final clinical trial guidance and a public hearing notice on the same day, and Executive Order 14401 directs priority review. Two hosts separate the regulatory reality from the headlines: where the law actually stands, what to tell a patient asking about ketamine clinics versus psilocybin trials, and which signals are worth watching.

Read the guide: https://psychnpfellowship.com/psychedelic-therapy-2026-pmhnp-regulatory-status/

Hey! I'd love to hear your thoughts, send me a voice note.

CMS put the CY 2027 conversion factor at $33.17 for qualifying APM participants and $32.84 for everyone else — cuts of 1.19% and 1.68%. Most of that drop isn't a new policy decision, it's a one-year 2.50% increase from CY 2026 expiring on schedule. Two hosts walk through what the proposed rule actually changes for psychiatric practice, which of the three shifts reaches your reimbursement first, and how to read a conversion factor cut without panicking about it.

Full breakdown: https://psychnpfellowship.com/medicare-2027-pfs-proposed-rule-pmhnp/

Hey! I'd love to hear your thoughts, send me a voice note.

Perinatal psychopharmacology for PMHNPs: which SSRI to start, how lamotrigine clearance shifts by trimester, lactation RID numbers, and when to escalate.

In this Deep Dive episode, two hosts walk through “Perinatal Psychopharmacology: PMHNP Protocol 2026” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC.

Key takeaways:

• Lamotrigine clearance climbs roughly 80% in the first trimester and about 200% by the second, so a stable preconception dose quietly becomes a subtherapeutic one.

• Sertraline and escitalopram are the preferred first-line SSRIs; sertraline's relative infant dose in breast milk is about 0.5%.

• ACOG advises against withholding or stopping psychiatric medication on the basis of pregnancy or lactation status alone.

• Valproate stays off the table: about 1-2% neural tube defect risk and malformation rates reported near 11% with first-trimester monotherapy.

• Postpartum psychosis hits 1-2 per 1,000 deliveries, usually inside the first two weeks, and is an emergency rather than a follow-up.

• The highest-yield visit is the one before conception, not the one at eight weeks gestation.

Read the full article: https://psychnpfellowship.com/perinatal-psychopharmacology-pmhnp-protocol-2026/

Explore the Psych NP Fellowship: https://psychnpfellowship.com/programs/

This content is for educational purposes and does not replace individualized clinical judgment or supervision.

Hey! I'd love to hear your thoughts, send me a voice note.

Medicare's Collaborative Care model needs a psychiatric consultant, and most PMHNPs qualify. How the role works, who bills, and how to contract for it.

In this Deep Dive episode, two hosts walk through “PMHNP Collaborative Care Consultant: 2026 Career Guide” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC.

Key takeaways:

• CMS defines the Collaborative Care psychiatric consultant as a medical provider trained in psychiatry and qualified to prescribe the full range of medications. Most PMHNPs meet that definition.

• The consultant usually never meets the patient. The job is a weekly caseload review with a behavioral health care manager, typically done remotely, plus quick questions between reviews.

• The primary care practice bills CPT 99492, 99493, 99494, or G2214. The consultant gets paid by that practice under a contract or employment agreement and does not bill Medicare for these codes.

• The University of Washington AIMS Center budgets 2 to 3 hours of consultant time per week for each full-time care manager.

• In the IMPACT trial, 45% of older adults in Collaborative Care had at least a 50% drop in depressive symptoms at 12 months, compared with 19% in usual care.

• The risk sits in the contract: scope rules in restricted-practice states, malpractice coverage for indirect consultation, and licensure where the patients live.

Read the full article: https://psychnpfellowship.com/pmhnp-collaborative-care-psychiatric-consultant-2026/

Explore the Psych NP Fellowship: https://psychnpfellowship.com/programs/

This content is for educational purposes and does not replace individualized clinical judgment or supervision.

Hey! I'd love to hear your thoughts, send me a voice note.

Medicare allows no-show fees, Medicaid doesn't, and a missed psych visit can signal real risk. The 2026 PMHNP no-show policy playbook for private practice.

In this Deep Dive episode, two hosts walk through “PMHNP No-Show Policy: A 2026 Private Practice Playbook” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC.

Key takeaways:

• At a 15 percent no-show rate, a solo PMHNP with 60 weekly follow-ups loses about 9 visits a week. At $150 a visit, that is roughly $65,000 a year.

• Medicare allows a missed-appointment fee only when one written policy and one dollar amount apply to every patient. Bill the patient directly and never submit it to Medicare.

• CMS policy bars billing Medicaid beneficiaries for missed appointments, whatever they signed. Exempt them, and dual-eligible patients, in writing.

• Patients with long-term mental health conditions who missed more than two primary care appointments a year had over 8 times the all-cause mortality risk of those who missed none, in a Scottish national study.

• Two text reminders cut missed appointments at four London community mental health clinics from 36 percent to 26 to 27 percent.

• Sequence matters: a clinician reviews high-risk no-shows the same day, and billing waits until that check is done.

Read the full article: https://psychnpfellowship.com/pmhnp-no-show-policy-private-practice-2026/

Explore the Psych NP Fellowship: https://psychnpfellowship.com/programs/

This content is for educational purposes and does not replace individualized clinical judgment or supervision.

Hey! I'd love to hear your thoughts, send me a voice note.

In this deep-dive episode, we unpack Countertransference as Clinical Data: A PMHNP Field Guide.

Audio Overview Listen to an in-depth podcast of this post Two hosts break down the full article — no reading required. Your browser does not support audio playback. TL;DR Countertransference is the clinician’s emotional reaction to a patient. It is not a professional failing — it is clinical data. Four reaction patterns (dread, savior pull, boredom, over-familiarity) signal specific diagnostic dynamics. A three-step in-session protocol — Notice, Name, Neutralize — takes under 90 seconds and builds a pattern library over months. Acting on countertransference without supervision is the clinical risk. Having it is not. Early-career PMHNPs who track reactions and bring them to supervision move from reactive to formulated practice within 18 months. In this guide What countertransference actuall

Read the full post: https://psychnpfellowship.com/countertransference-clinical-data-pmhnp/

Hey! I'd love to hear your thoughts, send me a voice note.

In this deep-dive episode, we unpack Saying No to Controlled Substances: A New PMHNP Confidence Script.

New PMHNPs get pressured, manipulated, and sometimes bullied into writing controlled substances they would not otherwise prescribe. Confidence is not about having a perfect answer — it is about having a rehearsed one. This post delivers a five-step refusal framework, exact patient-facing language, documentation pearls, and the mental reframe that stops most clinicians from caving under pressure.

Read the full post: https://psychnpfellowship.com/saying-no-controlled-substances-new-pmhnp-confidence-script/